Literature DB >> 32507548

A single psychotomimetic dose of ketamine decreases thalamocortical spindles and delta oscillations in the sedated rat.

A Mahdavi1, Y Qin2, A-S Aubry3, D Cornec3, S Kulikova4, D Pinault5.   

Abstract

BACKGROUND: In patients with psychotic disorders, sleep spindles are reduced, supporting the hypothesis that the thalamus and glutamate receptors play a crucial etio-pathophysiological role, whose underlying mechanisms remain unknown. We hypothesized that a reduced function of NMDA receptors is involved in the spindle deficit observed in schizophrenia.
METHODS: An electrophysiological multisite cell-to-network exploration was used to investigate, in pentobarbital-sedated rats, the effects of a single psychotomimetic dose of the NMDA glutamate receptor antagonist ketamine in the sensorimotor and associative/cognitive thalamocortical (TC) systems.
RESULTS: Under the control condition, spontaneously-occurring spindles (intra-frequency: 10-16 waves/s) and delta-frequency (1-4 Hz) oscillations were recorded in the frontoparietal cortical EEG, in thalamic extracellular recordings, in dual juxtacellularly recorded GABAergic thalamic reticular nucleus (TRN) and glutamatergic TC neurons, and in intracellularly recorded TC neurons. The TRN cells rhythmically exhibited robust high-frequency bursts of action potentials (7 to 15 APs at 200-700 Hz). A single administration of low-dose ketamine fleetingly reduced TC spindles and delta oscillations, amplified ongoing gamma-(30-80 Hz) and higher-frequency oscillations, and switched the firing pattern of both TC and TRN neurons from a burst mode to a single AP mode. Furthermore, ketamine strengthened the gamma-frequency band TRN-TC connectivity. The antipsychotic clozapine consistently prevented the ketamine effects on spindles, delta- and gamma-/higher-frequency TC oscillations.
CONCLUSION: The present findings support the hypothesis that NMDA receptor hypofunction is involved in the reduction in sleep spindles and delta oscillations. The ketamine-induced swift conversion of ongoing TC-TRN activities may have involved at least both the ascending reticular activating system and the corticothalamic pathway.
Copyright © 2018. Published by Elsevier B.V.

Entities:  

Keywords:  Clozapine; Midline thalamic nuclei; NMDA glutamate receptors; Quantitative EEG; Sleep; Thalamic reticular nucleus

Mesh:

Substances:

Year:  2020        PMID: 32507548     DOI: 10.1016/j.schres.2020.04.029

Source DB:  PubMed          Journal:  Schizophr Res        ISSN: 0920-9964            Impact factor:   4.939


  5 in total

1.  Network Asynchrony Underlying Increased Broadband Gamma Power.

Authors:  Nicolas Guyon; Leonardo Rakauskas Zacharias; Eliezyer Fermino de Oliveira; Hoseok Kim; João Pereira Leite; Cleiton Lopes-Aguiar; Marie Carlén
Journal:  J Neurosci       Date:  2021-02-16       Impact factor: 6.167

2.  Lysergic acid diethylamide differentially modulates the reticular thalamus, mediodorsal thalamus, and infralimbic prefrontal cortex: An in vivo electrophysiology study in male mice.

Authors:  Antonio Inserra; Danilo De Gregorio; Tamim Rezai; Martha Graciela Lopez-Canul; Stefano Comai; Gabriella Gobbi
Journal:  J Psychopharmacol       Date:  2021-03-01       Impact factor: 4.153

3.  The Impact of Sleep on Neurocognition and Functioning in Schizophrenia-Is It Time to Wake-Up?

Authors:  David Kimhy; Luz Ospina; Katie Beck-Felts; Ahmad Fakhoury; Anna E Mullins; Andrew W Varga
Journal:  J Psychiatr Brain Sci       Date:  2022-01-25

4.  Mathematical Model Insights into EEG Origin under Transcranial Direct Current Stimulation (tDCS) in the Context of Psychosis.

Authors:  Joséphine Riedinger; Axel Hutt
Journal:  J Clin Med       Date:  2022-03-26       Impact factor: 4.241

5.  Behavioral features and disorganization of oscillatory activity in C57BL/6J mice after acute low dose MK-801 administration.

Authors:  Keke Cui; Zhipeng Yu; Le Xu; Wangcong Jiang; Luwan Wang; Xiangqun Wang; Dandan Zou; Jiajie Gu; Feng Gao; Xiaoqing Zhang; Zhengchun Wang
Journal:  Front Neurosci       Date:  2022-09-14       Impact factor: 5.152

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.